Peterson Lance R, Schora Donna M
Departments of Medicine and Pathology, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
Department of Medicine, Division of Infectious Diseases, NorthShore University HealthSystem, Evanston, Illinois, USA.
J Clin Microbiol. 2016 Nov;54(11):2647-2654. doi: 10.1128/JCM.00698-16. Epub 2016 Jun 15.
Methicillin-resistant Staphylococcus aureus (MRSA) infection is a global health care problem. Large studies (e.g., >25,000 patients) show that active surveillance testing (AST) followed by contact precautions for positive patients is an effective approach for MRSA disease control. With this approach, the clinical laboratory will be asked to select what AST method(s) to use and to provide data monitoring outcomes of the infection prevention interventions. This minireview summarizes evidence for MRSA disease control, reviews the involvement of the laboratory, and provides examples of how to undertake a program cost analysis. Health care organizations with total MRSA clinical infections of >0.3/1,000 patient days or bloodstream infections of >0.03/1,000 patient days should implement a MRSA control plan.
耐甲氧西林金黄色葡萄球菌(MRSA)感染是一个全球性的医疗保健问题。大型研究(例如,超过25000名患者)表明,对阳性患者进行主动监测检测(AST)并采取接触预防措施是控制MRSA疾病的有效方法。采用这种方法时,临床实验室将被要求选择使用何种AST方法,并提供感染预防干预措施的数据监测结果。本综述总结了MRSA疾病控制的证据,回顾了实验室的参与情况,并提供了如何进行项目成本分析的示例。MRSA临床感染总数>0.3/1000患者日或血流感染>0.03/1000患者日的医疗保健机构应实施MRSA控制计划。